These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22920871)

  • 21. Adherence to combination antiretroviral therapy: synthesis of the literature and clinical implications.
    Miller LG; Hays RD
    AIDS Read; 2000 Mar; 10(3):177-85. PubMed ID: 10758022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda.
    Spacek LA; Shihab HM; Kamya MR; Mwesigire D; Ronald A; Mayanja H; Moore RD; Bates M; Quinn TC
    Clin Infect Dis; 2006 Jan; 42(2):252-9. PubMed ID: 16355337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of antiretroviral triple combinations including the protease inhibitor nelfinavir in heavily pretreated children with HIV-1 infection.
    Hoffmann F; Funk M; Linde R; Notheis G; Petropoulou T; Eberle J; Gürtler L; Belohradsky BH; Wintergerst U
    Eur J Med Res; 2002 Jul; 7(7):330-4. PubMed ID: 12176683
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antiretroviral salvage therapy for multiclass drug-resistant HIV-1-infected patients: from clinical trials to daily clinical practice.
    Imaz A; Falcó V; Ribera E
    AIDS Rev; 2011; 13(3):180-93. PubMed ID: 21799536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing resistance costs of antiretroviral therapies via measures of future drug options.
    Jiang H; Deeks SG; Kuritzkes DR; Lallemant M; Katzenstein D; Albrecht M; DeGruttola V
    J Infect Dis; 2003 Oct; 188(7):1001-8. PubMed ID: 14513420
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An audit of viral load in one clinical population to describe features of viraemic patients on antiretroviral therapy.
    Madge S; Smith CJ; Lampe F; Sabin CA; Youle M; Johnson MA; Phillips AN
    HIV Med; 2008 Apr; 9(4):208-13. PubMed ID: 18298577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Unexpected coreceptor usage of primary human immunodeficiency virus type 1 isolates from viremic patients under highly active antiretroviral therapy.
    Holtkamp N; Otteken A; Findhammer S; Miller V; Kurth R; Werner A
    J Infect Dis; 2000 Feb; 181(2):513-21. PubMed ID: 10669334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Effects of double and triple antiretroviral agents on the HCV viral load in patients coinfected with HIV and HCV].
    Gavazzi G; Richallet G; Morand P; Bouchard O; Bosseray A; Leclercq P; Micoud M
    Pathol Biol (Paris); 1998 Jun; 46(6):412-5. PubMed ID: 9769871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determinants of virological response to antiretroviral therapy: implications for long-term strategies.
    Deeks SG
    Clin Infect Dis; 2000 Jun; 30 Suppl 2():S177-84. PubMed ID: 10860903
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The amplitudes of viral blips in HIV-1 infected patients treated with antiretroviral therapy are power-law distributed.
    Percus JK; Percus OE; Di Mascio M
    J Theor Biol; 2009 Apr; 257(3):454-9. PubMed ID: 19171155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N; Pernas M; de la Rosa R; Gómez-Mariano G; Fernández G; Rubio A; López M; Benito JM; López-Galíndez C; Leal M; Domingo E; Martinez MA; Mas A
    J Med Virol; 2004 Jul; 73(3):350-61. PubMed ID: 15170628
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [HIV therapy of the next generation. Modern active drugs for long-term treatment].
    MMW Fortschr Med; 2012 May; 154 Suppl 1():50-1. PubMed ID: 22916603
    [No Abstract]   [Full Text] [Related]  

  • 34. [New drugs--hope for salvage patients?].
    Arastéh K; Müller M
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():38-41. PubMed ID: 16385871
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV treatment outcomes in Europe and North America: what can we learn from the differences?
    Ambrosioni J; Nicolas D; Agüero F; Manzardo C; Miro JM
    Expert Rev Anti Infect Ther; 2014 May; 12(5):523-6. PubMed ID: 24694073
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Potential new therapies for the treatment of HIV-1 infection.
    Condra JH; Miller MD; Hazuda DJ; Emini EA
    Annu Rev Med; 2002; 53():541-55. PubMed ID: 11818489
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Apropos of antiretroviral therapy of HIV infections. Interview by H. Allouch].
    Yeni P
    Presse Med; 1998 Nov; 27(34):1741-4. PubMed ID: 9835935
    [No Abstract]   [Full Text] [Related]  

  • 38. [As simple and as compatible as possible. HIV patients profit from single tablet regimen].
    MMW Fortschr Med; 2014 Jun; 156 Suppl 1():46-7. PubMed ID: 25026857
    [No Abstract]   [Full Text] [Related]  

  • 39. Antiretroviral update from the 46th ICAAC.
    Gallant JE
    Hopkins HIV Rep; 2007 Jan; 19(1):1-3, 12. PubMed ID: 17569167
    [No Abstract]   [Full Text] [Related]  

  • 40. [The concept of the new ERA study].
    Wolf E; Jaeger H
    MMW Fortschr Med; 2013 Jun; 155 Suppl 1():24-6. PubMed ID: 23961649
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.